SCHEMBL8390

SCHEMBL8390

NOCC(Cl)(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6548215 0.96
Water SCHEMBL11220624 0.96
SCHEMBL9098760 0.74
SCHEMBL787874 0.67
SCHEMBL13318807 0.67
SCHEMBL2873069 0.65
SCHEMBL15359393 0.64
SCHEMBL23302398 0.61
SCHEMBL2889249 0.61
SCHEMBL4691298 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12611461-B2 Bioorthogonal compositions TAMBO, INC. (US) 2026-04-28 US disclosed
US-12611462-B2 Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof CITY OF HOPE (US) 2026-04-28 US disclosed
US-12589162-B2 Trans-cyclooctene prodrug of monomethyl auristatin E TAMBO, INC. (US) 2026-03-31 US disclosed
US-12569466-B2 Short-acting psychoactive compounds of the MDMA class APOAPSIS HOLDINGS, LLC (US) 2026-03-10 US disclosed
US-12570621-B2 Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole APOAPSIS HOLDINGS, LLC (US) 2026-03-10 US disclosed
US-20260028662-A1 OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE PROMEGA CORP (US) 2026-01-29 US disclosed
US-12527874-B2 Bioorthogonal compositions TAMBO, INC. (US) 2026-01-20 US disclosed
US-20260007759-A1 TRANS-CYCLOOCTENE PRODRUG OF MONOMETHYL AURISTATIN E TAMBO, INC. 2026-01-08 US disclosed
US-20250378926-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC (US) 2025-12-11 US disclosed
US-20250368608-A1 SELECTIVE HDAC6 INHIBITOR ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2025-12-04 US disclosed
WO-2002030879-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-18 WO disclosed
WO-2002026696-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-04 WO disclosed
WO-2002026703-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN ETHER LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-04 WO disclosed
WO-2002008193-A2 THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-01-31 WO disclosed
WO-2001093841-A2 BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS NOVUSPHARMA S.P.A. (IT) 2001-12-13 WO disclosed
WO-2001080921-A2 NATIVE PROTEIN MIMETIC FIBERS, FIBER NETWORKS AND FABRICS FOR MEDICAL USE EMORY UNIVERSITY (US) 2001-11-01 WO disclosed
WO-2001078800-A1 ANTITHROMBOGENIC MEMBRANE MIMETIC COMPOSITIONS AND METHODS EMORY UNIVERSITY (US) 2001-10-25 WO disclosed
EP-0609058-B1 Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses SANKYO CO (JP) 1998-12-09 EP disclosed
US-5491167-A INHIBITORS OF CHOLESTEROL BIOSYNTHESIS SANKYO COMPANY, LIMITED (JP) 1996-02-13 US disclosed
EP-0609058-A2 Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-08-03 EP disclosed